TY - JOUR
T1 - Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer
AU - the American Joint Committee on Cancer Expert Panel on Cancers of the Lower Gastrointestinal, Anus Disease Site
AU - Janczewski, Lauren M.
AU - Faski, Joseph
AU - Nelson, Heidi
AU - Gollub, Marc J.
AU - Eng, Cathy
AU - Brierley, James D.
AU - Palefsky, Joel M.
AU - Goldberg, Richard M.
AU - Washington, M. Kay
AU - Asare, Elliot A.
AU - Goodman, Karyn A.
N1 - Publisher Copyright:
© 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including anal cancer, is the standard for cancer staging in the United States. The AJCC staging criteria are dynamic, and periodic updates are conducted to optimize AJCC staging definitions through a panel of experts charged with evaluating new evidence to implement changes. With greater availability of large data sets, the AJCC has since restructured and updated its processes, incorporating prospectively collected data to validate stage group revisions in the version 9 AJCC staging system, including anal cancer. Survival analysis using AJCC eighth edition staging guidelines revealed a lack of hierarchical order in which stage IIIA anal cancer was associated with a better prognosis than stage IIB disease, suggesting that, for anal cancer, tumor (T) category has a greater effect on survival than lymph node (N) category. Accordingly, version 9 stage groups have been appropriately adjusted to reflect contemporary long-term outcomes. This article highlights the changes to the now published AJCC staging system for anal cancer, which: (1) redefined stage IIB as T1–T2N1M0 disease, (2) redefined stage IIIA as T3N0–N1M0 disease, and (3) eliminated stage 0 disease from its guidelines altogether.
AB - The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including anal cancer, is the standard for cancer staging in the United States. The AJCC staging criteria are dynamic, and periodic updates are conducted to optimize AJCC staging definitions through a panel of experts charged with evaluating new evidence to implement changes. With greater availability of large data sets, the AJCC has since restructured and updated its processes, incorporating prospectively collected data to validate stage group revisions in the version 9 AJCC staging system, including anal cancer. Survival analysis using AJCC eighth edition staging guidelines revealed a lack of hierarchical order in which stage IIIA anal cancer was associated with a better prognosis than stage IIB disease, suggesting that, for anal cancer, tumor (T) category has a greater effect on survival than lymph node (N) category. Accordingly, version 9 stage groups have been appropriately adjusted to reflect contemporary long-term outcomes. This article highlights the changes to the now published AJCC staging system for anal cancer, which: (1) redefined stage IIB as T1–T2N1M0 disease, (2) redefined stage IIIA as T3N0–N1M0 disease, and (3) eliminated stage 0 disease from its guidelines altogether.
KW - American Joint Committee on Cancer (AJCC) version 9
KW - anal cancer
KW - cancer prognostication
KW - principles of cancer staging
KW - staging/tumor/node/metastasis (TNM) classification
UR - http://www.scopus.com/inward/record.url?scp=85157988552&partnerID=8YFLogxK
U2 - 10.3322/caac.21780
DO - 10.3322/caac.21780
M3 - Review article
AN - SCOPUS:85157988552
SN - 0007-9235
VL - 73
SP - 516
EP - 523
JO - Ca-A Cancer Journal for Clinicians
JF - Ca-A Cancer Journal for Clinicians
IS - 5
ER -